Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Impact Therapeutics (英派药业) IPO: Mind the Catalysts in 2H2026

Impact Therapeutics (英派药业) IPO Trading

Impact Therapeutics (英派药业) Pre-IPO: Post Senaparib Commercialization, What's Next?

Impact Therapeutics (英派药业) Pre-IPO: Credible R&D in PARP

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

IMPACT Therapeutics / Equity Capital Markets

<ul>
<li>Impact Therapeutics, a China-based near-commercial-stage biopharma company, is looking to raise at least USD 100 million via a Hong Kong listing. GS and CICC are the joint sponsors.</li>
<li>In our previous note, we looked at the company’s core products, its pre-IPO investors and management team. We also look at updates from its latest prospectus.</li>
<li>In this note, we provide an risk-adjusted SOTP valuation for the company.</li>
</ul>


Impact Therapeutics, a China-based near-commercial-stage biopharma company, is looking to raise at least USD 100 million via a Hong Kong listing. GS and CICC are the joint sponsors.
In our previous note, we looked at the company’s core products, its pre-IPO investors and management team. We also look at updates from its latest prospectus.
In this note, we provide an risk-adjusted SOTP valuation for the company.


Impact Therapeutics (英派药业) Pre-IPO: Thoughts on Valuation